Tocagen (TOCA) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Tocagen (NASDAQ:TOCA) from a hold rating to a buy rating in a research report sent to investors on Wednesday, March 14th. They currently have $15.00 price target on the stock.

According to Zacks, “Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company’s lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States. “

How to Become a New Pot Stock Millionaire

Other analysts also recently issued research reports about the company. BidaskClub upgraded Tocagen from a sell rating to a hold rating in a research note on Friday, March 9th. ValuEngine upgraded Tocagen from a strong sell rating to a sell rating in a research note on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Tocagen presently has an average rating of Buy and a consensus price target of $21.50.

TOCA traded down $0.41 during midday trading on Wednesday, reaching $10.99. 126,002 shares of the company’s stock traded hands, compared to its average volume of 106,933. The firm has a market capitalization of $226.99 and a price-to-earnings ratio of -4.13. The company has a debt-to-equity ratio of 0.05, a current ratio of 5.23 and a quick ratio of 5.23. Tocagen has a 52 week low of $8.60 and a 52 week high of $17.95.

Tocagen (NASDAQ:TOCA) last released its quarterly earnings results on Thursday, March 8th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.02). Tocagen had a negative net margin of 94,948.78% and a negative return on equity of 145.76%. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million. sell-side analysts expect that Tocagen will post -2.3 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its holdings in shares of Tocagen by 52.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 630,375 shares of the company’s stock valued at $7,886,000 after buying an additional 218,100 shares during the period. Goldman Sachs Group Inc. bought a new position in Tocagen in the 2nd quarter worth $366,000. Artal Group S.A. bought a new position in Tocagen in the 4th quarter worth $1,025,000. Blankinship & Foster LLC bought a new position in Tocagen in the 4th quarter worth $412,000. Finally, BBR Partners LLC raised its holdings in Tocagen by 278.7% in the 4th quarter. BBR Partners LLC now owns 54,887 shares of the company’s stock worth $563,000 after purchasing an additional 40,395 shares during the period. 32.78% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This piece was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at

Tocagen Company Profile

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Get a free copy of the Zacks research report on Tocagen (TOCA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with's FREE daily email newsletter.

Leave a Reply